EE143 Cost-Effectiveness of Ocrelizumab in First-Line Treatment of Highly Active Relapsing-Remitting Multiple Sclerosis in Chile
Jun 1, 2023, 00:00
10.1016/j.jval.2023.03.446
https://www.valueinhealthjournal.com/article/S1098-3015(23)00546-6/fulltext
Title :
EE143 Cost-Effectiveness of Ocrelizumab in First-Line Treatment of Highly Active Relapsing-Remitting Multiple Sclerosis in Chile
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)00546-6&doi=10.1016/j.jval.2023.03.446
First page :
Section Title :
Open access? :
No
Section Order :
11830